Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 231

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 231
---
 4:00 p.m., New York City time, on the applicable VWAP Purchase
Date, or such earlier time publicly announced by the Principal Market (or, if the Common Shares is then listed on an Principal Market,
by such Principal Market) as the official close of trading (regular way) on the Principal Market on such applicable VWAP Purchase Date.

<div align='center'>67</div>

Exhibit 99.4

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

<div align='center'>PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES

NLS PHARMACEUTICS LTD.</div>

Warrant Shares: [*]

Initial Exercise Date: [*],
2025

Issue Date: [*], 2025

THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c
of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [●] or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) until this Warrant
is exercised in full (the “Termination Date”), to subscribe for and purchase from NLS Pharmaceutics Ltd., a
corporation incorporated under the laws of Switzerland (the “Company”), up to [________] Common Shares (as subject
to adjustment hereunder